4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-20-031018
Chief R&D Officer sold 4,558 shares at $22.51 ($102,601)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan Chief R&D Officer | 2020-05-18 | Sale | −4,558 | $22.51 | $102,601 | 322,515 | D: show line 1 in the form |
| Open-market sales · 4,558 sh · avg $22.51 · $102,601 | |||||||
Loading xslF345X03/doc4.xml…